IL132463A0 - Lentivirus - based gene transfer vectors - Google Patents

Lentivirus - based gene transfer vectors

Info

Publication number
IL132463A0
IL132463A0 IL13246398A IL13246398A IL132463A0 IL 132463 A0 IL132463 A0 IL 132463A0 IL 13246398 A IL13246398 A IL 13246398A IL 13246398 A IL13246398 A IL 13246398A IL 132463 A0 IL132463 A0 IL 132463A0
Authority
IL
Israel
Prior art keywords
vector
eiav
expression system
lentivirus
genome
Prior art date
Application number
IL13246398A
Other languages
English (en)
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of IL132463A0 publication Critical patent/IL132463A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051Methods of production or purification of viral material
    • C12N2740/15052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL13246398A 1997-05-13 1998-05-12 Lentivirus - based gene transfer vectors IL132463A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4689197P 1997-05-13 1997-05-13
PCT/US1998/010144 WO1998051810A1 (en) 1997-05-13 1998-05-12 Lentivirus-based gene transfer vectors

Publications (1)

Publication Number Publication Date
IL132463A0 true IL132463A0 (en) 2001-03-19

Family

ID=21945954

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13246398A IL132463A0 (en) 1997-05-13 1998-05-12 Lentivirus - based gene transfer vectors

Country Status (13)

Country Link
US (3) US6277633B1 (xx)
EP (1) EP0981636B1 (xx)
JP (1) JP4390860B2 (xx)
KR (1) KR100556864B1 (xx)
CN (1) CN1247788C (xx)
AT (1) ATE291632T1 (xx)
AU (1) AU741747B2 (xx)
CA (1) CA2288328A1 (xx)
DE (1) DE69829471T2 (xx)
IL (1) IL132463A0 (xx)
NO (1) NO995382L (xx)
NZ (1) NZ500740A (xx)
WO (1) WO1998051810A1 (xx)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818209B1 (en) * 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US20040076613A1 (en) * 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
ATE298371T1 (de) * 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
GB2356200B (en) * 1997-12-22 2002-05-01 Oxford Biomedica Ltd Retroviral vectors
EP1042493A1 (en) * 1997-12-22 2000-10-11 Oxford Biomedica (UK) Limited Equine infectious anaemia virus (eiav) based retroviral vectors
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6790657B1 (en) 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
WO2000040741A2 (en) * 1999-01-07 2000-07-13 The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services, The National Institutes Of Health Lentivirus vector system
AU3893000A (en) * 1999-03-16 2000-10-04 Dana-Farber Cancer Institute, Inc. Lentiviral vector system for high quantity screening
CN1173036C (zh) * 1999-04-21 2004-10-27 卫生部艾滋病预防与控制中心 马传染性贫血病毒驴白细胞弱毒疫苗株的全长基因序列
DE60038971D1 (de) 1999-10-22 2008-07-03 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
CN1321182C (zh) * 1999-12-30 2007-06-13 卫生部艾滋病预防与控制中心 马传染性贫血病毒代表毒株的全基因克隆及其应用
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP1282702B1 (en) * 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU8710301A (en) * 2000-09-09 2002-03-22 Akzo Nobel Nv Eiav chimeric vaccine and diagnostic
GB0024550D0 (xx) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2002079482A2 (en) * 2000-11-16 2002-10-10 Rigel Pharmaceuticals, Inc. In vitro transcribed retroviral genomes, methods for their production and methods of use
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
EP1373536B9 (en) * 2001-03-13 2009-09-02 Novartis AG Lentiviral packaging constructs
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
IL161229A0 (en) * 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
CA2468861C (en) 2001-12-05 2012-06-12 The Regents Of The University Of California Robotic microscopy systems
EP1864691B1 (en) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
CN100340668C (zh) * 2002-04-26 2007-10-03 国家健康医学研究所 改进的嵌合糖蛋白和假型化慢病毒载体
AU2003291426A1 (en) * 2002-11-12 2004-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Human Services, The National Institutes Of Health Gp64-pseudotyped vectors and uses thereof
WO2004048583A2 (en) * 2002-11-22 2004-06-10 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US8026819B2 (en) * 2005-10-02 2011-09-27 Visible Assets, Inc. Radio tag and system
AU2004269233A1 (en) * 2003-08-29 2005-03-10 Kaneka Corporation Method of constructing transgenic bird using lentivirus vector and transgenic bird obtained thereby
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
WO2007089780A2 (en) * 2006-01-30 2007-08-09 Licentia, Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
US8105575B2 (en) * 2006-10-10 2012-01-31 Viromed Co., Ltd. Expression vectors with improved safety
EP2089513A1 (en) 2006-12-07 2009-08-19 Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
CN101705246B (zh) * 2007-04-29 2012-06-27 中国农业科学院哈尔滨兽医研究所 慢病毒基因转移载体、其制备方法和应用
US9593340B2 (en) 2007-10-15 2017-03-14 Admedus Vaccines Pty Ltd. Expression system for modulating an immune response
CA2705862C (en) 2007-11-16 2018-03-27 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP3441458B9 (en) 2009-02-03 2023-08-23 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
CN101532031B (zh) * 2009-03-03 2011-04-20 上海吉盛制药技术有限公司 非整合慢病毒载体系统及其制备与应用
WO2011034421A1 (en) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
EP2319918B1 (en) * 2009-11-10 2013-01-16 Centre National De La Recherche Scientifique Lentiviral-based vector and its use in directed evolution of genomic regions, genes and polynucleotides
WO2011066578A1 (en) * 2009-11-30 2011-06-03 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2012047093A1 (en) 2010-10-05 2012-04-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of the sjögren's syndrome
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
AU2013281328B2 (en) 2012-06-27 2017-11-23 Meiragtx Uk Ii Limited Combination for treating an inflammatory disorder
DK3103872T3 (en) 2012-07-12 2018-10-22 Proqr Therapeutics Ii Bv OLIGONUCLEOTIDES TO MAKE A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE IN A LIVING CELL
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
US9730996B2 (en) 2012-10-24 2017-08-15 Texas Biomedical Research Institute Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
TW201522637A (zh) 2013-03-15 2015-06-16 Jackson Lab 非胚胎幹細胞之單離及其用途
WO2015069469A1 (en) 2013-11-05 2015-05-14 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
AU2015247727A1 (en) 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
EP3242945B1 (en) 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
CN108883105B (zh) 2015-10-23 2022-07-15 杰克逊实验室 烟酰胺用于治疗和预防眼部神经退行性疾病如青光眼
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
CA3006779A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
EP4099015A1 (en) 2016-06-10 2022-12-07 Gadeta B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
US20190367944A1 (en) 2017-01-30 2019-12-05 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
JP2020530977A (ja) 2017-05-24 2020-11-05 ウニベルシダッド アウトノマ デ バルセロナ 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト
EP3648776A4 (en) 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CHS-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR THE THERAPY OF DISORDERS
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
CA3120923A1 (en) 2018-11-26 2020-06-04 Universitat Autonoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy
CA3120576A1 (en) 2018-11-26 2020-06-04 Massachusetts Institute Of Technology Compositions and methods for immune tolerance
CA3140507A1 (en) 2019-05-31 2020-12-03 Universitat Autonoma De Barcelona Insulin gene therapy
JP2023515711A (ja) 2020-04-27 2023-04-13 ユニヴァーシティ オブ アイオワ リサーチ ファウンデーション 組成物および嚢胞性線維症の処置のための方法
IL298532A (en) 2020-05-26 2023-01-01 Univ Barcelona Autonoma Gene therapy for diseases related to the central nervous system using fibroblast growth factor 21 (fgf21)
WO2021242719A1 (en) * 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
JP2023552531A (ja) 2020-12-10 2023-12-18 サレプタ セラピューティクス, インコーポレイテッド 接着細胞のための懸濁モードシードトレイン開発
WO2022162067A1 (en) 2021-01-30 2022-08-04 Universitat Autònoma De Barcelona Gene therapy for monogenic diabetes
WO2022221462A1 (en) 2021-04-13 2022-10-20 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or mcad and methods of using the same
EP4089171A1 (en) 2021-05-12 2022-11-16 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Recombinant tert-encoding viral genomes and vectors
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2023285700A1 (en) 2021-07-16 2023-01-19 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Oligonucleotide for inhibiting quaking activity
WO2023212683A1 (en) 2022-04-29 2023-11-02 Kriya Therapeutics, Inc. Insulin and glucokinase gene therapy compositions and its use for treating diabetes
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024052413A1 (en) 2022-09-07 2024-03-14 Universitat Autònoma De Barcelona Beta-hexosaminidase vectors
WO2024100136A1 (en) 2022-11-08 2024-05-16 Gadeta B.V. Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
JPH04503306A (ja) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス1型発現ベクター
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5376542A (en) 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
CA2158936C (en) 1993-11-18 2012-02-21 Jack R. Barber Compositions and methods for utilizing conditionally lethal genes
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5750396A (en) 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
US6150511A (en) 1995-05-09 2000-11-21 Fox Chase Cancer Center Chimeric enzyme for promoting targeted integration of foreign DNA into a host genome
WO1996035798A1 (en) 1995-05-10 1996-11-14 Introgene B.V. Improved retroviral vectors, especially suitable for gene therapy
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
HUP0000421A2 (hu) * 1996-10-17 2000-06-28 Oxford Biomedica (Uk) Limited Retrovirális vektorok

Also Published As

Publication number Publication date
EP0981636B1 (en) 2005-03-23
US6277633B1 (en) 2001-08-21
DE69829471D1 (de) 2005-04-28
ATE291632T1 (de) 2005-04-15
CA2288328A1 (en) 1998-11-19
NZ500740A (en) 2001-02-23
US6521457B2 (en) 2003-02-18
JP2002510199A (ja) 2002-04-02
CN1261404A (zh) 2000-07-26
KR20010012543A (ko) 2001-02-15
NO995382D0 (no) 1999-11-03
JP4390860B2 (ja) 2009-12-24
NO995382L (no) 2000-01-13
AU7577798A (en) 1998-12-08
WO1998051810A1 (en) 1998-11-19
CN1247788C (zh) 2006-03-29
KR100556864B1 (ko) 2006-03-10
EP0981636A1 (en) 2000-03-01
AU741747B2 (en) 2001-12-06
US20030148522A1 (en) 2003-08-07
DE69829471T2 (de) 2006-04-13
US20010044149A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
IL132463A0 (en) Lentivirus - based gene transfer vectors
EP0512017B1 (en) Vaccines
EP0702716A4 (en) GENTHERAPY FOR HIV INFECTION AND AIDS WITH THE AID OF RIBOZYMS
GB2331522B (en) Lentiviral vectors
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
CA2370103A1 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
GB8923123D0 (en) A vaccine for human immunodeficiency virus
WO2003092594A3 (en) Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
NZ316389A (en) Retroviral packaging plasmid and methods of use thereof
CA2104396A1 (en) Viral particles having altered host range
WO2001055362A3 (en) Hybrid adeno-retroviral vector for the transfection of cells
AUPN477695A0 (en) Gene therapy
Pietschmann et al. An evolutionarily conserved positively charged amino acid in the putative membrane-spanning domain of the foamy virus envelope protein controls fusion activity
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
EP1006196A3 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
EP3805385A1 (en) Lentiviral vector and method for delivering exogenous rna by the lentiviral vector
FR2606029B2 (fr) Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
CA2557882A1 (en) Defective packaging non-oncoviral vectors based on mpmv and hiv
AU4952500A (en) Packaging cell
WO2000040741A3 (en) Lentivirus vector system
WO2001044458A3 (en) Bovine immunodeficiency virus (biv) based vectors
WO2002008436A3 (en) Mini-adenoviral vector system for vaccination
Joshi et al. Efficient replication, integration, and packaging of retroviral vectors with modified long terminal repeats containing the packaging signal
AU8188187A (en) Viral vector and recombinant DNA coding, in particular, for the p25 protein of the virus that is a causal agent of aids, infected cell culture, protein obtained, vaccine and antibodies obtained
ATE342999T1 (de) Auf siv basierende verpackungsdefiziente vektoren